Slide background
Slide background
Slide background
Slide background
Slide background

Mission

HealthTell is committed to empowering the next generation of therapeutics and diagnostics for complex immune-mediated diseases such as cancer and autoimmune disorders.

Technology

HealthTell’s diverse chemical libraries enable highly accurate insights to inform early drug development and individual real-time immune response to inform presence and nature of specific diseases. The proprietary peptide arrays provide patterns with highly accurate insight into sequence binding which informs on/off target binding for drug discovery, and provides patterns which accurately inform presence and nature of specific diseases.

Our Mission

HealthTell is committed to empowering the next generation of therapeutics and diagnostics for complex immune-mediated diseases such as cancer and autoimmune disorders.

Technology Core

HealthTell’s diverse chemical libraries enable highly accurate insights to inform early drug development and individual real-time immune response to inform presence and nature of specific diseases. The proprietary peptide arrays provide patterns with highly accurate insight into sequence binding which informs on/off target binding for drug discovery, and provides patterns which accurately inform presence and nature of specific diseases.

The Power of Peptide Arrays

HealthTell’s proprietary arrays contain over 300,000 peptide chains synthesized on silicon chips. These peptides bind with specific disease antibodies and are illuminated during the analysis phase and classified based on a precise disease algorithm.

A New Disease Monitoring Platform

Scientific Proof of Concept & Applications
One Publication At a Time

publications-b-01

“Application of immunosignatures to the assessment of Alzheimer’s disease”

– Annals of Neurology, 2011
Authors: Restrepo L, Stafford P, Magee DM, Johnston SA.

Accurate assessment of Alzheimer’s disease (AD), both pre-symptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD…
View Publication

publications-b-01

“Scalable High-Density Peptide Arrays for Comprehensive Health Monitoring”

— Nature Communications, 2014
Authors: Legutki JB, Zhao ZG, Greving M, Woodbury N, Johnston SA, Stafford P.

There is an increasing awareness that health care must move from post-symptomatic treatment to presymptomatic intervention. An ideal system would allow regular inexpensive monitoring of health status using circulating antibodies to report on health fluctuations. Recently, we demonstrated that peptide microarrays can do this through antibody signatures (immunosignatures)…
View Publication

publications-b-01

“Application of immunosignatures to the assessment of Alzheimer’s disease”

– Annals of Neurology, 2011
Authors: Restrepo L, Stafford P, Magee DM, Johnston SA.

Accurate assessment of Alzheimer’s disease (AD), both pre-symptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD…
View Publication

publications-b-01

“Evaluation of Biological Sample Preparation for Immunosignature-Based Diagnostics”

— Clinical and Vaccine Immunology, 2012
Authors: Chase BA, Johnston SA and Legutki JB.

Immunosignatures derived from dried blood were capable of distinguishing naïve mice from those infected with influenza virus. Saliva was applied to the arrays, and the IgA immunosignature correlated strongly with that from dried blood…
View Publication

publications-b-01

“Feasibility of an early Alzheimer’s disease immunosignature diagnostic test”

— Journal of Neuroimmunology, 2012
Authors: Restrepo L, Stafford P, Johnston SA.

A practical diagnostic test is needed for early Alzheimer’s disease (AD) detection. Immunosignaturing, a technology that employs antibody binding to a random-sequence peptide microarray, generates profiles that distinguish transgenic mice engineered with familial AD mutations (APPswe/PSEN1-dE9)…
View Publication

publications-b-01

“Immunosignaturing: a critical review”

— Cell Press, 2012
Authors: Sykes K., Legutki JB, Stratford P.

Health is a complex interaction between metabolism, physiology, and immunity. Although it is difficult to define quantitatively, the activity of the humoral immune system provides a reasonable proxy for changes in health. Immunosignaturing is a microarray-based technology that quantitates the dynamics of circulating antibodies. Recent advancements in the field warrant a review of the technology…
View Publication

publications-b-01

“Immunosignatures can predict vaccine efficacy”

— PNAS, 2013
Authors: Legutki JB, Johnston SA.

Vaccines have been the most important medical intervention developed, yet vaccines for many diseases are still needed. Despite its success, the process to develop a vaccine remains empirical, resting on measuring the number of vaccinees that incur or do not incur an infection. Here we test in the mouse flu model whether the “immunosignature” diagnostic technology could be applied to predict vaccine efficacy…
View Publication

publications-b-01

“Application of Immunosignatures to Diagnosis of Valley Fever”

— Clinical and Vaccine Immunology, 2014
Authors: Navalkar KA, Johnston SA, Woodbury N, Galgiani J, Magee DM, Chicacz Z, Stafford P.

Valley fever (VF) is difficult to diagnose, partly because the symptoms of VF are confounded with those of other community-acquired pneumonias. Confirmatory diagnostics detect IgM and IgG antibodies against coccidioidal antigens via immunodiffusion (ID)…
View Publication

publications-b-01

“Diagnosis and Early Detection of CNS-SLE in MRL/lpr Mice Using Peptide Microarrays”

— BMC Immunology, 2014
Authors: Williams S, Stafford P, Hoffman SA.

These results indicate that immunosignaturing could predict and diagnose lupus and its CNS manifestations. It can also be used to characterize pathogenic autoantibodies, which may help to better understand the underlying mechanisms of CNS-Lupus. (PDF)
View Publication

publications-b-01

“Immunosignature System for Diagnosis of Cancer”

— PNAS, 2014
Authors: Stafford P, Cichacz Z, Woodbury N, Johnston SA.

Over much of the world, healthcare systems are facing an unprecedented challenge to meet the medical needs of an aging population while controlling costs. The early detection and treatment of diseases that are prevalent in older people is likely to be a key aspect of economically efficient, high-quality healthcare. In the case of cancer, the resection of a stage I or stage II tumor is often effectively a cure…
View Publication

World Class Technology that Provides Highly Valuable Information for Drug DevelopmentPassionate About Improving Healthcare

“HealthTell provides valuable insights into drug development, disease, and wellness”

Bill Colston, PhD
CEO, HealthTell

About Our Leadership Team

HealthTell Investors Include:

 

About Our Investors

HealthTell is collaborating with world renown universities, hospitals, and clinical researchers. Our technology has endless possible applications to impact clinical utility, drug development, and biotechnology.

About Our Partnerships

Our Vision

“HealthTell will revolutionize disease diagnostics.”

– Bill Colston, PhD
CEO, HealthTell

Our leadership team is inspired to change the diagnostic industry forever. From early detection to better health economics, HealthTell is built on the foundation that improving the technology and experience available to patients today, will help them live better, healthier tomorrow.

About Our Leadership Team

Clinical Advisors

“A technology capable of detecting the presence of disease, with a simple drop of blood, would revolutionize cancer diagnosis.”

– Paul A. Bunn, Jr., MD
Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research

HealthTell continues to partner with world renown leaders in the healthcare industry who are motivated to improve outcomes nad decrease expenditures by leveraging the power of ImmunoSignatures.

Learn more about Our Clinical Advisors

Board of Directors

“Investment in a company is more than just the financial returns, it is also about the societal impact the company hopes to make with their technology. HealthTell will disrupt disease diagnostics providing a needed improvement in medicine.”

– Paul Conley, PhD
Managing Director, Paladin Capital Group

About Our Board of Directors

Investors

HealthTell Investors Include:

About Our Investors

Collaborators

HealthTell is collaborating with world renown universities, hospitals, and clinical researchers. Our technology has endless possible applications to impact clinical utility, drug development, and biotechnology.

About Our Partnerships

Join our Team

HealthTell is a company filled with passionate, data driven, and collaborative professionals, considered world class in their area of expertise. We are hiring people with entrepreneurial spirits to help develop new applications for our platform that positively impact people’s health.

HealthTell has two regional sites in San Ramon, California and Chandler, Arizona. These locations are strategically designed to provide access to key industry talent in business, technical, and manufacturing disciplines.

Want to be an integral part of the diagnostic revolution? Please explore our open career opportunities or feel free to contact us for further information.





General/ProductClinicianInvestorsPress/News InformationScientific/CollaboratorsOther


captcha